• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    NGM Biopharmaceuticals, Inc. - Common Stock (NQ: NGM )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Apr 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open -
    Bid (Size) 1.550 (545)
    Ask (Size) 1.610 (1)
    Prev. Close 1.540
    Today's Range N/A - N/A
    52wk Range 0.8288 - 2.200
    Shares Outstanding 78,049,340
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NGM Bio Announces Closing of Tender Offer
    From NGM Biopharmaceuticals, Inc.
    Via GlobeNewswire
    NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
    From NGM Biopharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    More News

    Read More
    NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Looking Into NGM Biopharmaceuticals's Recent Short Interest
    Via Benzinga
    Why NGM Biopharmaceuticals Stock Is Blasting Higher
    Via Benzinga
    NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
    From NGM Biopharmaceuticals, Inc.
    Via GlobeNewswire
    NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Why Is Cancer-Focused NGM Biopharmaceuticals Stock Trading Lower On Monday?
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), NGM Biopharmaceuticals, Inc. (Nasdaq – NGM), VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
    From NGM Biopharmaceuticals, Inc.
    Via GlobeNewswire
    NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
    From NGM Biopharmaceuticals, Inc.
    Via GlobeNewswire
    NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
    From NGM Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Why JetBlue Airways Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
    From NGM Biopharmaceuticals, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    B. Riley Securities Maintains Buy Rating for NGM Biopharmaceuticals: Here's What You Need To Know
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
    From NGM Biopharmaceuticals, Inc.
    Via GlobeNewswire
    NGM Bio to Participate in Upcoming Investor Conferences
    From NGM Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.